Thus, targeting the FGF-2/FGFR1/pericyte/CXCL14/TAMs axis provides a potentially novel and rational approach for treating NPC and other FGF-2–expressing tumors. This evidence concerns the gene FGF2 and nasopharyngeal carcinoma.